Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lipocine Inc.LPCN · Entity 7696 | Principal Accounting Officer | December 18, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lipocine Inc.
Report date December 18, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.20 · Expires 2035-12-18 | Direct | 40,146 |
Reported balance
After 2025-12-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-18 · Grant · Acquired 20,786 · Balance 40,146 F1: Subject to vesting whereby 1/3 of the shares subject to the award will vest on December 18, 2026, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorated basis over the following two years. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to vesting whereby 1/3 of the shares subject to the award will vest on December 18, 2026, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorated basis over the following two years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2025 Filed Dec 19, 2025 22:07 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 20,786 | $4.20 Strike: $4.20 | $87,301.20 |
DisclosureSEC source: 0001493152-25-028593 · ownership.xml · derivative · entry 1 Fogarty Krista · CIK 0001906986 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,146 Underlying: Common Stock · 20,786 shares Expires 2035-12-18 F1 · derivative.expiration_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on December 18, 2026, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorated basis over the following two years. Read SEC document |
| December 23, 2024 Filed Dec 31, 2024 01:03 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 5,943 | $4.80 Strike: $4.80 | $28,526.40 |
DisclosureSEC source: 0001493152-24-052575 · ownership.xml · derivative · entry 1 Fogarty Krista · CIK 0001906986 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,460 Underlying: Common Stock · 5,943 shares Expires 2034-12-23 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on December 23, 2025, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorated basis over the following two years. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 21:51 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock | 991 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-009705 · ownership.xml · nonDerivative · entry 1 Fogarty Krista · CIK 0001906986 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,727 F1 · shares: Restricted stock unit subject to vesting whereby 1/3 of the shares subject to the award will vest on the one-year anniversary of March 8, 2025, while the remaining 2/3 of the shares subject to the award will vest semi-annually on a prorated basis over the following two years. Read SEC document |
| December 22, 2022 Filed Dec 23, 2022 00:18 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 91,850 | $0.41 Strike: $0.41 | $37,658.50 |
DisclosureSEC source: 0001493152-22-036371 · ownership.xml · derivative · entry 1 Fogarty Krista · CIK 0001906986 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,850 Underlying: Common Stock · 91,850 shares Expires 2032-12-22 F1 · derivative.expiration_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 22, 2023, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorated basis over the following two years. Read SEC document |
| May 17, 2022 Filed May 17, 2022 20:58 UTC | Lipocine Inc. LPCN · Entity 7696 | PurchaseCommon Stock | 12,500 | $0.86 | $10,750.00 |
DisclosureSEC source: 0001493152-22-014199 · ownership.xml · nonDerivative · entry 1 Fogarty Krista · CIK 0001906986 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.